Evidence map›Paper›PMID 42443966›Full record

ArticleJournal of intensive care2026

Mean arterial pressure-to-norepinephrine-equivalent dose ratio, rather than achieved mean arterial pressure alone, is associated with mortality in septic shock.

Xiaojun Zhao, Bo-Yang Wang, Shi-Tong Diao, Yangyanqiu Wang, Mao-Mao Cao, Yan Chen, Tian-Yuan Zhu, Rong Liufu, Shan Li, Chun-Yao Wang and 5 more

Abstract read
In one paragraph

Article in Journal of intensive care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Xiaojun ZhaoDepartment of Medical Intensive Care Unit, State Key Laboratory of Complex Severe and Rare Diseases, Critical and Emergency Pharmaceuticals & Medical Devices Innovation Lab, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.
Bo-Yang WangDepartment of Medical Intensive Care Unit, State Key Laboratory of Complex Severe and Rare Diseases, Critical and Emergency Pharmaceuticals & Medical Devices Innovation Lab, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.
Shi-Tong DiaoDepartment of Medical Intensive Care Unit, State Key Laboratory of Complex Severe and Rare Diseases, Critical and Emergency Pharmaceuticals & Medical Devices Innovation Lab, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.
Yangyanqiu WangDepartment of Medical Intensive Care Unit, State Key Laboratory of Complex Severe and Rare Diseases, Critical and Emergency Pharmaceuticals & Medical Devices Innovation Lab, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.
Mao-Mao CaoDepartment of Medical Intensive Care Unit, State Key Laboratory of Complex Severe and Rare Diseases, Critical and Emergency Pharmaceuticals & Medical Devices Innovation Lab, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.
Yan ChenDepartment of Medical Intensive Care Unit, State Key Laboratory of Complex Severe and Rare Diseases, Critical and Emergency Pharmaceuticals & Medical Devices Innovation Lab, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.
Tian-Yuan ZhuDepartment of Medical Intensive Care Unit, State Key Laboratory of Complex Severe and Rare Diseases, Critical and Emergency Pharmaceuticals & Medical Devices Innovation Lab, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.
Rong LiufuDepartment of Medical Intensive Care Unit, State Key Laboratory of Complex Severe and Rare Diseases, Critical and Emergency Pharmaceuticals & Medical Devices Innovation Lab, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.
Shan LiDepartment of Medical Intensive Care Unit, State Key Laboratory of Complex Severe and Rare Diseases, Critical and Emergency Pharmaceuticals & Medical Devices Innovation Lab, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.
Chun-Yao WangDepartment of Medical Intensive Care Unit, State Key Laboratory of Complex Severe and Rare Diseases, Critical and Emergency Pharmaceuticals & Medical Devices Innovation Lab, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.
Wen-Ying HanDepartment of Medical Intensive Care Unit, State Key Laboratory of Complex Severe and Rare Diseases, Critical and Emergency Pharmaceuticals & Medical Devices Innovation Lab, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.
Wei JiangDepartment of Medical Intensive Care Unit, State Key Laboratory of Complex Severe and Rare Diseases, Critical and Emergency Pharmaceuticals & Medical Devices Innovation Lab, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.
Bin DuDepartment of Medical Intensive Care Unit, State Key Laboratory of Complex Severe and Rare Diseases, Critical and Emergency Pharmaceuticals & Medical Devices Innovation Lab, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China. dubin98@gmail.com.ORCID http://orcid.org/0000-0001-6237-2895
Li WengDepartment of Medical Intensive Care Unit, State Key Laboratory of Complex Severe and Rare Diseases, Critical and Emergency Pharmaceuticals & Medical Devices Innovation Lab, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China. wengli@gmail.com.ORCID http://orcid.org/0000-0003-0403-0752
China Critical Care Clinical Trials Group (CCCCTG)

Funding

National High Level Hospital Clinical Research Funding (2025-PUMCH-A-133), Beijing Natural Science Foundation 7264310National Key R&D Programme from the Ministry of Science and Technology (MoST): Prevention and Control of Emerging and Major Infectious Diseases 2025ZD01903000Noncommunicable Chronic Diseases-National Science and Technology Major Project 2023ZD0506505The Beijing High-Level Innovation and Entrepreneurship Talent Support Program-Healthcare Platform leading talent projects G202512005
6 · The paper itself

Abstract

backgroundHigher mean arterial pressure (MAP) is commonly pursued in septic shock, yet randomized trials have failed to demonstrate a survival benefit-and patients achieving higher MAP often exhibit paradoxically greater mortality. We hypothesized this reflects impaired vascular responsiveness requiring greater vasopressor support, quantifiable by the MAP-to-norepinephrine-equivalent dose ratio (MAP/NEQ).

methodsWe conducted a retrospective cohort study using two independent critical care databases (MIMIC‑IV and eICU). Adult patients with septic shock receiving vasopressors within 24 h of ICU admission were included. The primary exposure was the 24-h time-weighted average MAP (65-80 mmHg vs. ≥ 80 mmHg); the key secondary exposure was MAP/NEQ. The primary outcome was 28-day mortality. Cox regression, restricted cubic splines, and mediation analysis were performed.

resultsA total of 7433 patients were included (MIMIC‑IV: n = 4944; eICU: n = 2489). Despite being younger with fewer comorbidities, patients with MAP ≥ 80 mmHg had higher 28-day mortality (MIMIC-IV: 19.5% vs. 12.6%; eICU: 20.5% vs. 11.0%; both P < 0.001). After adjustment for MAP/NEQ, the association between high MAP and mortality became non-significant, while MAP/NEQ remained independently and inversely associated with mortality in both cohorts (AUC 0.81 and 0.72). Mediation analyses revealed a suppression effect (- 33% and - 26%), indicating higher MAP coexisted with impaired vascular responsiveness. Subgroup and sensitivity analyses were consistent.

conclusionsHigher achieved MAP was not independently associated with 28-day mortality after accounting for vascular responsiveness. MAP/NEQ may serve as a clinically accessible tool for early risk stratification and identification of a vasoplegic phenotype in septic shock, though prospective validation is needed before clinical application.

Indexed as

MAP/NEQMean arterial pressureMortalitySeptic shockVasopressor responsiveness

Identifiers

PMID42443966
PMCPMC13520486

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.